查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1610264

胸膜炎治療市場：按診斷、治療、給藥方法和最終用戶分類 - 全球預測 2025-2030

Pleurodynia Treatment Market by Diagnosis (Blood Test, Culture Test, X-ray), Treatment (Analgesics, Immunoglobulin), Mode Of Administration, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，胸膜炎治療市值為1.3843億美元，預計到2024年將達到1.454億美元，複合年成長率為5.66%，到2030年將達到2.0354億美元。

胸膜炎，俗稱博恩霍姆病，是一種急性病毒感染疾病，會導致下胸部和上腹部嚴重肌肉疼痛。它通常由柯薩奇 B 病毒引起，治療重點是症狀管理而不是徹底治療。胸膜炎治療的需要源自於急性且常常使人衰弱的症狀，這些症狀嚴重限制了患者的運動能力和生活品質。治療主要是安寧療護，使用止痛藥和發炎藥物來緩解疼痛和減少發炎。最終用途包括提供初級和支持性護理的醫院、診所和門診機構。

主要市場統計
基準年[2023] 1.3843億美元
預測年份 [2024] 1.454 億美元
預測年份 [2030] 20354萬美元
複合年成長率（%） 5.66%

市場成長受到病毒感染疾病爆發和對有效疼痛管理解決方案日益成長的需求的影響。關鍵的成長要素包括抗病毒治療的進步、對病毒感染影響的認知以及有助於更好管理方法的快速診斷方法的發展。機會包括開發更有效的抗病毒藥物、針對病毒根源的治療方法以及快速止痛解決方案的創新。該公司的主要機會包括多元化發展非處方疼痛管理解決方案，以及與醫療提供者合作提供全面的護理服務。

然而，對胸膜炎流行病學的了解有限以及現有治療方法的潛在副作用等挑戰限制了成長。由於具體治療方法有限且該疾病依賴對症治療，因此有人指出需要研究新的治療方法。新藥的監管障礙和嚴格的核准程序也可能抑制市場勢頭。

預計創新的領域包括開發標靶抗病毒療法和探索使用生物技術來增強疼痛管理解決方案並使治療更安全、更有效。由於這個市場以患者為中心，往往強調症狀緩解，因此快速識別胸膜透析的增強診斷工具有可能顯著改善患者預後並推動市場擴張。由於該市場的高度專業化性質，製藥公司和醫療保健組織之間建立牢固的夥伴關係對於促進永續成長和解決治療差異至關重要。

市場動態：揭示快速發展的胸膜炎治療市場的關鍵市場洞察

供需的動態交互作用正在改變胸膜炎治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 病毒感染疾病和胸膜炎盛行率增加
    • 活性化新藥引進的研發活動
  • 市場限制因素
    • 研發成本上升
  • 市場機會
    • 醫療成果的技術進步與現代化
  • 市場問題
    • 嚴格的監管指引

波特的五力：駕馭胸膜炎治療市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解胸膜炎治療市場的外部影響

外部宏觀環境因素在塑造胸膜炎治療市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析：了解胸膜炎治療市場的競爭格局

對胸膜炎治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：胸膜炎治療市場供應商的績效評估

FPNV定位矩陣是評估胸膜炎治療市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製胸膜炎治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，胸膜炎治療市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：詳細檢視當前市場環境，主要企業的廣泛資料，評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、主要產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3. 塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 病毒感染疾病和胸膜炎盛行率增加
      • 活性化新藥引進的研發活動
    • 抑制因素
      • 研發活動成本上升
    • 機會
      • 醫療成果的技術進步與現代化
    • 任務
      • 嚴格的監管指引
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章胸膜炎治療市場：依診斷

  • 介紹
  • 驗血
  • 文化測試
  • X光

第7章胸膜炎治療市場：依治療分類

  • 介紹
  • 止痛藥
  • 免疫球蛋白

第8章胸膜炎治療市場：依給藥方式分類

  • 介紹
  • 注射
  • 口服

第9章胸膜炎治療市場：依最終使用者分類

  • 介紹
  • 醫院
  • 藥局

第10章美洲胸膜炎治療市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太胸膜炎治療市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的胸膜炎治療市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Alkem Laboratories Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Hetero Drugs
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck and Co. Inc.
  • Novartis AG
  • Opsonin Pharma Ltd.
  • Pfizer Inc.
  • Reckitt Benckiser Group PLC
  • Sanofi SA
Product Code: MRR-742BD51839D5

The Pleurodynia Treatment Market was valued at USD 138.43 million in 2023, expected to reach USD 145.40 million in 2024, and is projected to grow at a CAGR of 5.66%, to USD 203.54 million by 2030.

Pleurodynia, commonly known as Bornholm disease, is an acute viral infection leading to severe muscle pain in the lower chest and upper abdomen. Often caused by Coxsackie B viruses, its treatment primarily focuses on symptom management rather than a definitive cure. The necessity of pleurodynia treatment arises from its acute, often debilitating symptoms, which can severely restrict patient mobility and quality of life. Applications of treatment are mainly palliative, involving analgesics and anti-inflammatory medications, to alleviate pain and reduce inflammation. The end-use scope includes hospitals, clinics, and outpatient settings where primary and supportive care are administered.

KEY MARKET STATISTICS
Base Year [2023] USD 138.43 million
Estimated Year [2024] USD 145.40 million
Forecast Year [2030] USD 203.54 million
CAGR (%) 5.66%

Market growth is influenced by the prevalence of viral infections and the increasing demand for effective pain management solutions. Key growth factors include advancements in antiviral therapies, awareness of viral infection ramifications, and the development of rapid diagnostics contributing to better management practices. Opportunities arise in creating more effective antiviral drugs or therapies targeting the root viral causes, along with innovations in fast-acting pain relief solutions. For businesses, diversification into over-the-counter pain management solutions and partnerships with healthcare providers for comprehensive care packages present key opportunities.

However, challenges such as limited understanding of the epidemiology of pleurodynia, coupled with potential side effects of existing treatments, pose growth constraints. Limited specific drug treatments and reliance on symptomatic relief indicate the need for novel therapeutic research. Regulatory hurdles and stringent approval processes for new drug entities may also dampen market momentum.

Promising areas for innovation include developing targeted antiviral therapies and exploring the use of biotechnology to enhance pain management solutions, making treatments safer and more efficient. As the market is patient-centric with an inclination towards symptomatic relief, enhanced diagnostic tools to rapidly identify pleurodynia can significantly elevate patient outcomes and drive market expansion. The nature of this market is highly specialized, emphasizing the creation of robust partnerships between pharmaceutical entities and healthcare institutions to drive sustained growth and address treatment gaps.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pleurodynia Treatment Market

The Pleurodynia Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of viral infections and increasing prevalence of pleurodynia disease
    • Rising R&D activities for introducing new medications
  • Market Restraints
    • Rise in the cost of research and development activities
  • Market Opportunities
    • Technological advancements and modernization in the healthcare outcomes
  • Market Challenges
    • Stringent regulatory guidelines

Porter's Five Forces: A Strategic Tool for Navigating the Pleurodynia Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pleurodynia Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pleurodynia Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pleurodynia Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pleurodynia Treatment Market

A detailed market share analysis in the Pleurodynia Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pleurodynia Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pleurodynia Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Pleurodynia Treatment Market

A strategic analysis of the Pleurodynia Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Pleurodynia Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alkem Laboratories Limited, Cipla Limited, Dr. Reddy's Laboratories, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Hetero Drugs, Johnson & Johnson Services, Inc., Lupin Limited, Merck and Co. Inc., Novartis AG, Opsonin Pharma Ltd., Pfizer Inc., Reckitt Benckiser Group PLC, and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Pleurodynia Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Diagnosis, market is studied across Blood Test, Culture Test, and X-ray.
  • Based on Treatment, market is studied across Analgesics and Immunoglobulin.
  • Based on Mode Of Administration, market is studied across Injections and Oral.
  • Based on End-User, market is studied across Hospitals and Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of viral infections and increasing prevalence of pleurodynia disease
      • 5.1.1.2. Rising R&D activities for introducing new medications
    • 5.1.2. Restraints
      • 5.1.2.1. Rise in the cost of research and development activities
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements and modernization in the healthcare outcomes
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory guidelines
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pleurodynia Treatment Market, by Diagnosis

  • 6.1. Introduction
  • 6.2. Blood Test
  • 6.3. Culture Test
  • 6.4. X-ray

7. Pleurodynia Treatment Market, by Treatment

  • 7.1. Introduction
  • 7.2. Analgesics
  • 7.3. Immunoglobulin

8. Pleurodynia Treatment Market, by Mode Of Administration

  • 8.1. Introduction
  • 8.2. Injections
  • 8.3. Oral

9. Pleurodynia Treatment Market, by End-User

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Pharmacy

10. Americas Pleurodynia Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Pleurodynia Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Pleurodynia Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Alkem Laboratories Limited
  • 3. Cipla Limited
  • 4. Dr. Reddy's Laboratories
  • 5. GlaxoSmithKline PLC
  • 6. Glenmark Pharmaceuticals Limited
  • 7. Hetero Drugs
  • 8. Johnson & Johnson Services, Inc.
  • 9. Lupin Limited
  • 10. Merck and Co. Inc.
  • 11. Novartis AG
  • 12. Opsonin Pharma Ltd.
  • 13. Pfizer Inc.
  • 14. Reckitt Benckiser Group PLC
  • 15. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. PLEURODYNIA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. PLEURODYNIA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES PLEURODYNIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES PLEURODYNIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. PLEURODYNIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. PLEURODYNIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PLEURODYNIA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PLEURODYNIA TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY BLOOD TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY CULTURE TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY X-RAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES PLEURODYNIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. PLEURODYNIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 189. PLEURODYNIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023